Overview

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

: The purpose of this study is to test whether blinatumomab in combination with TKI therapy (such as dasatinib) is an effective treatment for people with Ph+ ALL. Researchers want to improve the response to standard-of-care treatment of corticosteroids + TKI therapy by adding the study drug, blinatumomab.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Amgen

Treatments:

Antibodies, Bispecific
Blinatumomab
Dasatinib
Dexamethasone
Methotrexate